Why PepsiCo and Realty Income Are May 2026's Top Picks for Dividend Investors
New York, Monday, 25 May 2026.
In May 2026, analysts highlight PepsiCo and Realty Income as prime dividend buys. Realty Income’s staggering 667-month payout streak offers a rare, highly reliable income opportunity at a discount.
Realty Income’s Defensive Appeal and Valuation
Realty Income (NYSE: O) has built a formidable reputation around its reliable monthly dividend distributions, commonly referring to itself as ‘The Monthly Dividend Company’ [GPT]. As an S&P 500 Dividend Aristocrat, the retail-focused real estate investment trust (REIT) has increased its dividend for more than 31 consecutive years [5]. In April 2026, the company distributed a monthly dividend of $0.271 per share, marking a steady climb from $0.264 in January 2025 and $0.228 in January 2020 [5]. Currently, the stock offers a robust dividend yield evaluated between 5.05% and 5.2% depending on daily market fluctuations [1][4][5]. This consistency is underpinned by a “Safe” dividend safety rating, an A- credit rating, and a comfortable adjusted funds from operations (AFFO) payout ratio of approximately 75.1% recorded in the first quarter of 2025 [5].
PepsiCo’s Steady Growth and Dividend King Status
Transitioning from real estate to consumer staples, PepsiCo (NASDAQ: PEP) stands out as a premier defensive asset. Headquartered in Purchase, New York, the company operates globally through major segments including PepsiCo Beverages North America, Europe, Middle East and Africa (EMEA), and Latin America Foods [3]. PepsiCo holds the prestigious title of a “Dividend King,” having delivered over 50 consecutive years of annual dividend increases [1][4]. The stock currently boasts a dividend yield of 3.8%, supported by a conservative payout ratio that accounts for 66% of its estimated 2026 earnings [1][2][3][4].
Market Performance and Strategic Moves
As of May 25, 2026, PepsiCo’s shares traded at $150.30, giving the firm a massive market capitalization of $205.79 billion and a price-to-earnings ratio of 23.65 [3]. Trading activity remained robust, with daily volumes reaching 7.78 million shares compared to an average of 7.16 million, and shares hitting an intraday high of $150.84 [3]. The stock’s current valuation—sitting comfortably within its 52-week range of $127.60 to $171.48—has prompted analysts to evaluate its fair value around the $150 mark, noting potential upside following a highly successful earnings quarter and the rollout of new health-focused products [3].